Co-targeting the PI3K and MEK pathways in NSCLC: an in vitro evaluation and mutation prevalence in an Irish patient cohort

被引：0
|
作者：
Heavey, S. [1 ]
Barr, M. P. [1 ,2 ]
Hennessy, B. [3 ]
Toomey, S. [3 ]
Carr, A. [3 ]
Crown, J. [4 ]
Finn, S. [1 ]
Cuffe, S. [1 ,2 ]
O'Byrne, K. J. [5 ]
Gately, K. A. [1 ,2 ]
机构：
[1] Univ Dublin Trinity Coll, Dublin 2, Ireland
[2] St James Hosp, HOPE Directorate, Dublin 8, Ireland
[3] Royal Coll Surgeons Ireland, Dublin 2, Ireland
[4] St Vincents Hosp, Dublin 4, Ireland
[5] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia
来源：
LUNG CANCER | 2014年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [41] Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma
    Steinbrunn, Torsten
    Stuehmer, Thorsten
    Sayehli, Cyrus
    Chatterjee, Manik
    Einsele, Hermann
    Bargou, Ralf C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 (04) : 430 - 440
  • [42] Co-Targeting MAP Kinase and Pi3K-Akt-mTOR Pathways in Meningioma: Preclinical Study of Alpelisib and Trametinib
    Mondielli, Gregoire
    Mougel, Gregory
    Darriet, Florent
    Roche, Catherine
    Querdray, Adeline
    Lisbonis, Christophe
    Appay, Romain
    Dufour, Henry
    Chinot, Olivier
    Graillon, Thomas
    Barlier, Anne
    CANCERS, 2022, 14 (18)
  • [43] Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity
    Watson, Adrienne L.
    Anderson, Leah K.
    Greeley, Andrew D.
    Keng, Vincent W.
    Rahrmann, Eric P.
    Halfond, Amanda L.
    Powell, Natasha M.
    Collins, Margaret H.
    Rizvi, Tilat
    Moertel, Christopher L.
    Ratner, Nancy
    Largaespada, David A.
    ONCOTARGET, 2014, 5 (06) : 1502 - 1514
  • [44] Models for evaluation of the biological consequences of mutations at the RAS/Raf/MEK/ERK and PI3K/AKT pathways in AML
    Libra, M.
    Stivala, F.
    Steelman, L.
    Abrams, S.
    Bertrand, F.
    Basecke, J.
    Jucker, M.
    Shelton, J.
    Molton, S.
    McMahon, M.
    McCubrey, J.
    ANNALS OF HEMATOLOGY, 2006, 85 : 15 - 16
  • [45] JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: A rationale for co-targeting these pathways in metastatic breast cancer
    Britschgi, Adrian
    Andraos, Rita
    Brinkhaus, Heike
    Klebba, Inna
    Murakami, Masato
    Romanet, Vincent
    Mueller, Urs
    Radimerski, Thomas
    Bentires-Alj, Mohamed
    CANCER RESEARCH, 2013, 73 (08)
  • [46] TARGETING THE PI3K/AKT/MTOR SIGNALING PATHWAYS IN CYSTIC FIBROSIS
    Reilly, R.
    Mroz, M.
    Dempsey, E.
    Shields, S.
    Wynne, K.
    McKone, E. F.
    Hiebel, C.
    Behl, C.
    Coppinger, J.
    PEDIATRIC PULMONOLOGY, 2016, 51 : 200 - 200
  • [47] Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways
    Lackner, Mark R.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2010, 10 (01) : 75 - 87
  • [48] Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells
    Du, Wei
    Pang, Changhe
    Xue, Yake
    Zhang, Qingjun
    Wei, Xinting
    ONCOLOGY LETTERS, 2015, 10 (05) : 3266 - 3270
  • [49] Role of the Raf/MEK/ERK and the PI3K/Akt(PKB) pathways in fibroblast senescence
    Lorenzini, A
    Tresini, M
    Mawal-Dewan, M
    Frisoni, L
    Zhang, H
    Allen, RG
    Sell, C
    Cristofalo, VJ
    EXPERIMENTAL GERONTOLOGY, 2002, 37 (10-11) : 1149 - 1156
  • [50] Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma
    May, Caitlin D.
    Landers, Sharon M.
    Bolshakov, Svetlana
    Ma, XiaoYan
    Ingram, Davis R.
    Kivlin, Christine M.
    Watson, Kelsey L.
    Al Sannaa, Ghadah A.
    Bhalla, Angela D.
    Wang, Wei-Lien
    Lazar, Alexander J.
    Torres, Keila E.
    CANCER BIOLOGY & THERAPY, 2017, 18 (10) : 816 - 826
12345